Home/Hepalys/Ryutaro Shimazaki

RS

Ryutaro Shimazaki

Chief Development Officer

Therapeutic Areas

Hepatology Metabolic Diseases

Hepalys Pipeline

Drug	Indication	Phase
Lanifibranor	Metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis	Phase 3

Leadership Team at Hepalys

BT Slingsby, MD, PhD, MPH

Chief Executive Officer & Co-Founder

Takeshi Takahashi, MBA

Chief Operating Officer & Co-Founder

Chief Commercial Officer

Yoshiro Banno, MPH

Chief Financial Officer

View full Hepalys profile